Vol 2, No 3 (2011)
Conference report / Report
Published online: 2011-10-18
The highlights of ASCO and EHA conferences on chronic myeloid leukemia in 2011
Hematologia 2011;2(3):276-283.
Abstract
This article provides an overview of the most important abstracts from ASCO and EHA conferences
in 2011, with special emphasis on 2nd generation tyrosine kinase inhibitors (TKI) as
first-line treatment of newly diagnosed chronic myeloid leukemia (CML) patients, problem of
resistance to imatinib including patients with T315I mutation, and consequences of resistance
of CML stem cell to TKI.
Hematologia 2011; 2, 3: 276–283
Hematologia 2011; 2, 3: 276–283
Keywords: chronic myeloid leukemiaimatinibnilotinibdasatinibT315I mutationleukemic stem cells
